TENX Stock Analysis: Buy, Sell, or Hold?
TENX - Tenax Therapeutics, Inc.
$15.99
1.98 (14.13%)
▲
5d:
+20.86%
30d:
+37.61%
90d:
+31.28%
HOLD
MODERATE Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When TENX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: TENX is 7.7% above fair value ($14.84). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: TENX is 7.7% above fair value ($14.84). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: TENX is currently trading at $15.99, which is considered extended relative to its 30-day fair value range of $11.81 to $14.84.
Technical Outlook: Technically, TENX is in a uptrend. The price is approaching resistance at $16.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.1% recently.
Market Sentiment: TENX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.57 (+111.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TENX is in a uptrend. The price is approaching resistance at $16.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.1% recently.
Market Sentiment: TENX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.57 (+111.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$11.81 -
$14.84
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+7.7% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+14.1%)
- BULLISH: Trading 111.1% below Wall St target ($29.57)
- CAUTION: Extended 7.7% above fair value - wait for pullback
Fair Price Analysis
30-Day Fair Range
$11.81 -
$14.84
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$13.22
Resistance Level
$16.27
Current Trend
Uptrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.58
Wall Street Target
$29.57
(+111.1%)
Share & Embed Analysis
Last updated: March 31, 2026 4:03 PM ET
Data refreshes hourly during market hours. Next update: 5:03 PM
Data refreshes hourly during market hours. Next update: 5:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TENX showing a specific setup today?
Insider Activity (6 Months)
9
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Stuart Rich
BUY
2500 shares
2025-12-08
Stuart Rich
BUY
2500 shares
2025-12-04
Stuart Rich
BUY
1500 shares
2025-12-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 54 HOLD |
